DERM — Journey Medical Corporation

Summary of Journey Medical's Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenues: $61.9 million for 2025, up 10% from $56.1 million in 2024.
• Net Product Revenue: Growth driven primarily by the launch of Emrosi, which generated $14.7 million in net sales since its launch in March 2025.
• Gross Margin: Improved to 66.2% from 62.8% in 2024, attributed to a favorable product mix and reduced inventory costs.
• SG&A Expenses: Increased to $44.4 million, reflecting costs associated with Emrosi's launch.
• GAAP Net Loss: Narrowed to $11.4 million ($0.47 per share) from $14.7 million ($0.72 per share) in 2024.
• Adjusted EBITDA: Positive at $2.9 million for 2025, compared to $800,000 in 2024.

2. Strategic Updates and Business Highlights

• Emrosi Launch: Successfully launched as a best-in-class oral treatment for rosacea, achieving approximately 53,000 prescriptions in its first nine months.
• Market Access: Approximately 100 million commercial lives have access to Emrosi, with contracts in place with two of the top three group purchasing organizations (GPOs).
• Physician Adoption: Ended 2025 with over 3,500 unique prescribers, exceeding initial targets.
• Clinical Validation: Positive Phase III trial results published in JAMA Dermatology, enhancing Emrosi's credibility and market position.
• Future Product Launches: Plans to introduce 1-2 additional dermatology products in 2026.

3. Forward Guidance and Outlook

• 2026 Expectations: Anticipates continued sales growth for Emrosi, with expectations for positive adjusted EBITDA and improved reimbursement rates as coverage expands.
• Prescription Growth: Expects to surpass the annualized run rate of 126,000 prescriptions based on Q4 performance.
• Sales Force Expansion: Plans to increase the sales team to support further growth.

4. Bad News, Challenges, or Points of Concern

• Generic Competition: The Accutane franchise and other legacy products are under pressure due to generic competition.
• Q1 2026 Prescription Trends: Initial Q1 prescription volume may be affected by insurance deductible resets and seasonal factors, although management expects growth to resume.
• Gross to Net Pressure: Current gross to net revenue per script has been lower than expected due to reimbursement dynamics and reliance on co-pay assistance programs.

5. Notable Q&A Insights

• Prescription Trends: Management acknowledged that Q1 may start slow due to seasonal factors but expects a strong rebound in March and continued growth throughout the year.
• Reimbursement Dynamics: The company is optimistic about improving gross to net ratios as it gains better coverage from health plans and GPOs.
• Inventory Management: The increase in accounts receivable was attributed to timing issues rather than operational concerns, and cash collection is expected to improve in Q1 2026.
• Market Positioning: Emrosi's efficacy and safety profile compared to competitors like Oracea were emphasized as key drivers for physician adoption and patient satisfaction.

Overall, Journey Medical reported a strong year with significant progress in launching Emrosi, improving financial metrics, and positioning for future growth, despite facing challenges from competition and market dynamics.